API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.
Lead Product(s): Glycine,Calcium
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Nozohaem
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: $48.6 million Upfront Cash: $48.6 million
Deal Type: Acquisition September 05, 2023
Details:
Data for Prothione (Glutathione) capsules, show that patients assigned treatment with the drug had a reduction in time to clinical resolution as defined by time to attain 3 consecutive negative RT-PCR tests and a statistically significant decrease in viral load of COVID-19.
Lead Product(s): L-Glutamic Acid,L-Cysteine,Glycine
Therapeutic Area: Infections and Infectious Diseases Product Name: Prothione
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022